Trice Medical was founded to fundamentally improve orthopedic diagnostics.

Michael Schrauben is the Director of Asset Allocation for MERS. He brings valuable global macroeconomic insight to the group, which facilitates strategic decision making and portfolio asset allocation. Michael co-manages the Fund’s internal equity program and also oversees the Fund’s Diversifying Strategies portfolio, which targets uncorrelated alternative investment strategies to reduce portfolio beta and drawdown. He manages the Asset Allocation Team, which monitors the Fund’s asset allocation and risk and provides allocation recommendations to the Portfolio Review Committee. He is a voting member on the Portfolio Review Committee, which is responsible for all portfolio management decisions including external asset manager selection and monitoring. Michael joined MERS in 2008.

Education

• BA with High Honors, Finance – Michigan State University, Eli Broad College of Business
• Michigan State University Financial Markets Institute
• Michigan State University Honors College

Professional Designation

• Chartered Financial Analyst (CFA) Charterholder

Sarah has twelve years of International Sales and Marketing experience in Healthcare. Her background is a strong mix of developing customer relationships, launching products, strategic planning and industry knowledge.

She spent nine years in Sports Medicine Orthopedics working in Sales and Marketing at Smith and Nephew, and more recently starting her own business focusing on bringing innovative sports medicine technologies into Europe. Sarah moved from the UK to Malvern, PA in 2018 to join the leadership team at Trice Medical.

Sarah holds a Psychology BSc from University of Surrey, UK.

Stuart is a serial entrepreneur who has started multiple companies over the last 25 years. He has devoted his time to creating companies within various fields. One of the roles that he is enjoys within an organization is developing sales teams and is currently the Executive Vice President of Therapeutics for Trice.

He joined Trice medical after the acquisition of his latest company SegWAY Orthopaedics. He has spent the last 6 years as CEO and Founder of SegWAY. Stuart has taken SegWAY from its infancy to one of the world’s fastest growing endoscopic release companies. He developed multiple surgeries within a platform and managed to get them through all aspects from regulatory, quality, sales and marketing. He has developed a large worldwide distributor network which carries the SegWAY surgical product line.

Prior to arriving in the United States from South Africa in 1996 Stuart had been in the South African Police force and had started companies since he was in high school.

Vasant brings extensive experience in R&D and technology. Prior to Smith & Nephew, Vasant was Senior Vice President of Technical Operations at Thoratec Corporation, a leader in mechanical circulatory support solutions for the treatment of heart failure. In this role, he provided leadership to a 600 member team, with responsibility for global R&D, Program Management, Operations and Quality. Prior to Thoratec, Vasant had an 18-year career at Medtronic, starting as a Staff Scientist and, progressing through more senior roles, ultimately becoming Vice President of Product Development for the Implantable Defibrillator Business. Vasant holds a Ph.D degree in Biomedical Engineering from Rutgers University, USA and an MBA degree from the Carlson School of Management, Minnesota.

Randy joined Garheng in starting HealthQuest in 2013. After a successful career as a MedTech entrepreneur, Randy switched careers because he also saw the opportunities overlooked by investors and felt that he could help innovative young businesses by applying the lessons he had learned by leading those kinds of companies. He is currently on the board of HealthQuest portfolio companies Vestagen, Virmedica, Avizia, Springbuk and Magnolia Medical and is a Board Observer at Trice Medical.

Randy’s industry successes include starting NovaMin Technology, Inc. leading it through financing, growth and eventual acquisition by GlaxoSmithKline (at a 10x return on capital), a turn-around of USBiomaterials Corp’s bone-grafting business from perennial money-loser to a profitable spin-out (now NovaBone Products) and being a member of the early management team at LensCrafters as it emerged from start-up to market leader. These businesses each solved real problems for patients and users and represent the kind of opportunities that Randy seeks as he thinks about opportunities at HealthQuest.

Randy is committed to supporting entrepreneurs both in HealthQuest’s portfolio and beyond, including as past chair of the Gainesville Area Innovation Network, and  advisory board member for the Florida Institute for the Commercialization of Public Research.

Randy graduated from Georgia Tech with a BS in Management Science. He spent the first half of his career in consumer products marketing, starting in brand management at Procter & Gamble. Randy lives in Gainesville, Florida with his wife when he’s not living out of a tent as he hikes and explores the backcountry.

Alan Davis, MD, is a highly regarded orthopaedic surgeon at the Cleveland Clinic, as well as a team physician for the United States Olympic Team. He was an Academic All-American and Captain of one of Michigan State’s most successful football teams. He has been involved in multiple medical and metabolic technologies including those related to sports drinks and the metabolic needs of high performance athletes, as well as computerized software design for maximized bio mechanical muscle training. Dr. Davis is also a member of the Orthopaedic and Rheumatologic Peer Review Committee, which is part of the Cleveland Clinic Innovation. The committee evaluates any new ideas for new devices or products.

Gary has 25+ years of experience in operations and investments. He joined Safeguard in 2006 where he is responsible for identifying, deploying capital in and supporting emerging healthcare companies in diagnostics, medical devices and healthcare IT. Gary is currently a board member of Safeguard partner companies Aktana, Good Start Genetics, MedCrypt, Medivo, Moxe Health, meQuilibrium, Propeller Health, Syapse and Trice Medical and is a board observer at Velano Vascular and Zipnosis. He is also a board chairman at Oncora Medical, a digital health start-up offering solutions for radiation oncology. He recently realized successful exits with partner companies Advanced BioHealing, Alverix, Avid Radiopharmaceuticals, Crescendo Biosciences and NuPathe to strategic acquirers Shire, Becton Dickinson, Eli Lilly, Myriad, and Teva, respectively. Gary joined Safeguard from BioAdvance, a state initiative committed to funding early-stage life sciences companies, where he served as Managing Director and Chief Operating Officer.

Previously, he was Chief Executive Officer at Pluvita Corporation, a company developing personalized medicine solutions and served as Chief Operating Officer at Genovo, and head of research & development at Avigen, both development stage gene therapy companies. Gary began his career in industry with Gilead Sciences as virology group leader. Gary received his MD degree from Washington University, trained in internal medicine at Barnes Hospital in St. Louis, MO, and completed hematology sub-specialty training at Stanford. He participated in post-doctoral research at both Stanford and the NIH. Gary currently involves himself with a number of entrepreneurs and entrepreneurial activities and is currently a lecturer in the Health Care Systems Department at the Wharton School at the University of Pennsylvania where he teaches an interdisciplinary graduate level course in healthcare entrepreneurship.

Craig Carra has spent the majority of his twenty year career holding various executive level positions with emerging growth, medical device and service companies. Craig’s career started as an auditor with Coopers & Lybrand (PricewaterhouseCoopers).

From 1996-2002, Craig served as Corporate Controller and Treasurer for Surgical Laser Technologies (SLT), a medical device company where he lead operational efficiencies with strict cash flow management to restore this turn-around Company and enabled it to grow through acquisition.

From 2002-2012, Craig served as VP Sales and Business Development for PhotoMedex (NASDAQ: PHMD). Combining his financial and operational background with his strategic thinking and leadership ability, Craig built a strong U.S. sales team and developed new business models to significantly increase both annual recurring revenue and capital equipment sales.

Prior to Trice, Craig served as the CFO and also led Business Development for Ella Health, a venture backed, healthcare services company. At Ella Health, he was responsible for securing new equity and debt financing to support the growth of the business and was successful in establishing strategic partnerships with physicians to open several new health centers.

Craig holds an Executive MBA Degree from Villanova University and is a CPA.

Mr. Intintoli joined Trice Medical in March of 2015 as Vice President of Engineering. He brings thirty-five years of professional experience in optical and medical device development. His unique combination of engineering, operations, regulatory and clinical skills has formed Trice’s current world-class development team and product supply chain.

Mr. Intintoli spent the prior thirteen years leading a team at PhotoMedex developing and building their surgical product offerings. Prior to PhotoMedex, he held ever-increasing engineering and operational roles with Surgical Laser Technologies, Quantronix Corporation, Kearfott Division of the Singer Company and the Laboratory of Laser Energetics.

Mr. Intintoli has a B.S. degree in optical engineering (with distinction) from the University of Rochester Institute of Optics. He is a fellow of the American Society for Laser Medicine and Surgery and a member of other optical societies.

Mark is an experienced professional with twenty years of progressively increasing responsibility in the medical device industry. Mark brought a unique combination of sales, marketing, operational and strategic planning skills to Trice Medical. Since Joining Trice in 2016, the organization has evolved into a technology company that has a broad portfolio of products for minimally invasive diagnostic and therapeutic orthopedic procedures.

Prior to joining Trice, he spent eight years helping to build Smith & Nephew’s U.S. Sports Medicine Division to the powerhouse that it is today. In his last role there, he was responsible for all U.S. Commercial Operations (roughly $600M.) Mark also worked on M&A activities and served as the U.S. Commercial Integration Lead for Smith and Nephew’s largest acquisition, Arthrocare.

Prior to Smith & Nephew, Mark spent eight years with Boston Scientific in roles of increasing responsibility within the Gastroenterology and Neurovascular Divisions.
Mark is a graduate of the University of Richmond where he earned his B.A.